<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02636634</url>
  </required_header>
  <id_info>
    <org_study_id>P071243</org_study_id>
    <secondary_id>2009-014458-14</secondary_id>
    <nct_id>NCT02636634</nct_id>
  </id_info>
  <brief_title>Non Invasive Methods for Differential Diagnosis Radionecrosis/Recurrence After Radiosurgery of Brain Metastases</brief_title>
  <acronym>CV-METANEC</acronym>
  <official_title>Non Invasive Methods for Differential Diagnosis Radionecrosis/Recurrence After Radiosurgery of Brain Metastases. CV-METANEC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this multicenter study is to assess a diagnostic strategy concerning&#xD;
      differential diagnosis between radiation necrosis and relapse in brain metastases treated&#xD;
      with radiosurgery. Two non-invasive tests - positron emission tomography (PET) with&#xD;
      1F-fluoro-ethyl-tyrosine (FET) and magnetic resonance spectroscopy (MRS) - will be compared&#xD;
      to histology in a cohort of patients presenting growing lesions 6 months after radiosurgical&#xD;
      treatment.&#xD;
&#xD;
      The results of this study should help to earlier diagnosis of recurrences after radiosurgery&#xD;
      and to perform an appropriate treatment for patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to assess a diagnostic strategy by monitoring brain metastases&#xD;
      after radio surgical treatment . Data from two non-invasive techniques: PET-FET (positron&#xD;
      emission tomography using 1-Fluoro-Ethyl-Tyrosine) and MSR (magnetic resonance spectroscopy)&#xD;
      will be compared to histological examination (gold standard) in patients with active&#xD;
      persistent and increased lesion 4 months after radiosurgery. The study should develop a&#xD;
      decision-making algorithm based on non-invasive tests and allow improving the length and&#xD;
      quality of life of these patients.&#xD;
&#xD;
      Early differential diagnosis between relapse and radio necrosis after radiosurgery would&#xD;
      allow:&#xD;
&#xD;
        -  To perform resection of tumor relapse&#xD;
&#xD;
        -  To treat feasable/inoperable tumor relapse with a salvage radiosurgery&#xD;
&#xD;
        -  To avoid irradiation for patients presenting radiation necrosis&#xD;
&#xD;
        -  To reduce the corticosteroid prescription period. Validation of non-invasive diagnostic&#xD;
           tools should in fine avoid biopsy. In addition, the results of this study should help to&#xD;
           better estimate the true incidence of radiation necrosis and better specify the&#xD;
           predictors of this complication.&#xD;
&#xD;
      CV-METANEC is a prospective, multicenter, open, multidisciplinary study involving the&#xD;
      following departments: neurosurgery, neuroradiology, nuclear medicine and neuropathology.&#xD;
&#xD;
      4 centers participating in the study: Groupe Hospitalier Pitié-Salpêtrière University&#xD;
      Hospital, Lariboisière Hospital, Lille University Hospital of Clermont Ferrand and Toulouse&#xD;
      University Hospital.&#xD;
&#xD;
      Patients are included if they were treated by radiosurgery for one or more brain metastases.&#xD;
      The interval between the radiosurgical treatment and the inclusion is at least 6 months. The&#xD;
      lesion is clinically and / or MRI evolving.&#xD;
&#xD;
      The criterion used to measure the discriminating power of the algorithm to rank the&#xD;
      differential between recurrences with or without radionecrosis or only radionecrosis is the&#xD;
      area under the ROC (receiver operating characteristic) curve. The inclusion of 90 subjects&#xD;
      will achieve a standard deviation of the area under the curve 0.04.&#xD;
&#xD;
      The duration of study participation will be five weeks, from inclusion until the end of&#xD;
      hospitalization. Subsequently, the patient will be followed as usual.&#xD;
&#xD;
      Inclusion D0: whether the conditions of inclusion are applied, the patient signs the consent&#xD;
      form and exams before surgery are planned: SRI-MRI, examination of scintigraphy and&#xD;
      anesthesia consultation.&#xD;
&#xD;
      D15: MRI (neuroradiology) and anesthetic consultation (neurosurgery).&#xD;
&#xD;
      D30-D33 (+/- 7 days): 3 days of hospitalization:&#xD;
&#xD;
      D30: MRI / MRS always done before-FET PET D31: stereotactic biopsy for histological samples.&#xD;
      D33: CT scan before the patient is discharged. Total study duration: 5 years&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the choline /N-acetyl aspartate ratio at MR spectroscopy</measure>
    <time_frame>Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the lipid / lactate ratio at MR spectroscopy</measure>
    <time_frame>Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>peak creatine at MR spectroscopy</measure>
    <time_frame>Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>lesional tissue / normal tissue ratio at PET with FET</measure>
    <time_frame>Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Histological result at biopsy</measure>
    <time_frame>Day 31</time_frame>
    <description>histology as the gold standard for the diagnostic between radiation necrosis and relapse</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Brain Metastases</condition>
  <condition>Growing Lesions After Radiosurgical Treatment</condition>
  <arm_group>
    <arm_group_label>diagnostic imaging strategy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PET-FET (positron emission tomography using 1-Fluoro-Ethyl-Tyrosine) and MSR (magnetic resonance spectroscopy) before biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>imaging</intervention_name>
    <arm_group_label>diagnostic imaging strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age between 18 and 75 years.&#xD;
&#xD;
          -  Patient treated with radiosurgery for one or more brain metastases Free -Intervally&#xD;
             between radiosurgical treatment and inclusion in the study at least four months.&#xD;
&#xD;
          -  Lesion (S) treated (s) and followed (s) with the criteria for a clinically active&#xD;
             lesion (progressive deficit, seizures, intracranial hypertension steroid-dependent)&#xD;
             and / or MRI (increased volume of contrast enhancement with peri-lesional edema and&#xD;
             mass effect on two successive examinations at 1 month interval).&#xD;
&#xD;
          -  Karnofsky index&gt; 50.&#xD;
&#xD;
          -  Prognostic compatible for survival with a follow-up at least three months from the&#xD;
             date of inclusion.&#xD;
&#xD;
          -  Effective contraception for women of childbearing potential or negative pregnancy test&#xD;
             within 72 hours.&#xD;
&#xD;
          -  Signed informed consent obtain&#xD;
&#xD;
          -  Affiliation to the social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to MRI examination&#xD;
&#xD;
          -  Clearance of the creatinine incompatible with the injection of gadolinium&#xD;
&#xD;
          -  No potential follow-up in middle or long term&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles-Ambroise VALERY, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Pitié-Salpêtrière - Service de Neurochirurgie du Pr Philippe Cornu - Babinsky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Pitié-Salpêtrière - Service de Neurochirurgie du Pr Philippe Cornu - Babinsky</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>December 8, 2015</study_first_submitted>
  <study_first_submitted_qc>December 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2015</study_first_posted>
  <last_update_submitted>April 8, 2016</last_update_submitted>
  <last_update_submitted_qc>April 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diagnostic strategy</keyword>
  <keyword>brain metastases</keyword>
  <keyword>radiation necrosis</keyword>
  <keyword>relapse</keyword>
  <keyword>PET-FET and MSR</keyword>
  <keyword>radiosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

